Amakem – Exit
Amakem is using it’s Localized Drug Action platform for the development of kinase inhibitors. The primary focus is on eye disease.
| Sector: | Ophthalmology |
| Country: | Belgium |
| Status: | Assets outlicensed |
Vesalius Biocapital offers venture capital
to young European innovative life science companies